LAS VEGAS, NV, June 02, 2026 /24-7PressRelease/ -- New Horizon Medical Solutions (NHMS) announces the promotion of Raymond Jessen, MPH, MHSA, CTBS, to Senior Vice President of Compliance, Regulatory Affairs & Quality. The promotion recognizes Raymond's leadership in building NHMS's compliance infrastructure and advancing regulatory strategy across medical devices and HCT/Ps.

"Raymond has raised the bar for how we approach compliance and quality at every level of the organization. This promotion reflects the trust we place in his judgment and his impact on our growth." - Will Hall, CEO, NHMS

"In this new position Raymond brings a level of precision and accountability to regulatory standards that is rare. He has strengthened our governance framework and that will directly reduce enterprise risk." - Bart J. Verdirame, General Counsel, NHMS

In his expanded role, he will oversee regulatory strategy, the quality management system, and compliance infrastructure, including inspection readiness, product lifecycle planning, and risk mitigation. He brings more than 25 years of experience from organizations including Intermountain Health, Smith & Nephew, PolarityBio, and Genpact, with a track record spanning thousands of regulatory submissions across medical devices, HCT/Ps, and pharmaceuticals.

Areas of expertise include:
• Regulatory strategy and submissions for medical devices, HCT/Ps, and pharmaceuticals
• FDA and CMS inspection readiness and compliance infrastructure
• Quality system development and scalable operations
• Product lifecycle planning and HRO implementation
• Enterprise recall management and supply chain quality

"Building compliance infrastructure that enables growth while protecting patients is work I am deeply committed to. I look forward to advancing that mission with this exceptional team." - Raymond Jessen, SVP of Compliance, Regulatory Affairs & Quality, NHMS

About New Horizon Medical Solutions
New Horizon Medical Solutions is a forward-thinking company specializing in advanced wound care technologies, committed to developing and delivering biologically derived human placental allograft products that meet the highest safety and performance standards. NHMS's product portfolio includes amniotic tissues, micro autologous skin grafting, and wound care devices for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. Through evidence-based design and quality manufacturing, NHMS strives to enhance patient outcomes in clinical practice.

# # #